Bionano Genomics (BNGO) EBITDA Yield: History & Chart

Bionano Genomics, Inc.(BNGO)

Medical - Instruments & Supplies · San Diego, CA

$1.46+0.01 (+1.03%)

Delayed quote: Oct 6, 2026, 10:15 AM EDT

About Bionano Genomics, Inc.

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

San Diego, CA

96 employees

bionano.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Albert A. Luderer

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Bionano Genomics, Inc. (BNGO)	$16.75M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.86M	N/A	1.21%	1.72%	1.72%
BioCardia, Inc. (BCDA)vs ›	$16.22M	N/A	7.50%	7.48%	7.48%
Lipocine Inc. (LPCN)vs ›	$17.07M	N/A	6.12%	6.12%	6.12%
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.80M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.57M	N/A	N/A	N/A	N/A
Marker Therapeutics, Inc. (MRKR)vs ›	$17.76M	N/A	N/A	N/A	N/A
Pasithea Therapeutics Corp. (KTTA)vs ›	$15.27M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.18M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.28M	N/A	0.87%	0.87%	0.87%

NAME

MARKET CAP

EBITDA YIELD

TTM

Bionano Genomics, Inc. (BNGO)

$16.75M

N/A

Dyadic International, Inc. (DYAI)vs ›

$16.86M

N/A

1.21%

1.72%

BioCardia, Inc. (BCDA)vs ›

$16.22M

N/A

7.50%

7.48%

Lipocine Inc. (LPCN)vs ›

$17.07M

N/A

6.12%

Allarity Therapeutics, Inc. (ALLR)vs ›

$15.80M

N/A

Cocrystal Pharma, Inc. (COCP)vs ›

$15.57M

N/A

Marker Therapeutics, Inc. (MRKR)vs ›

$17.76M

N/A

Pasithea Therapeutics Corp. (KTTA)vs ›

$15.27M

N/A

Karyopharm Therapeutics Inc. (KPTI)vs ›

$15.18M

N/A

Citius Pharmaceuticals, Inc. (CTXR)vs ›

$14.28M

N/A

0.87%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

BNGO EBITDA Yield Metrics

BNGO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics